Ospedale S. Eugenio

Running trials

• Recruiting

  European Myeloma Network (EMN) Sample Project

  NCT06237803· Source

• Recruiting

  Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.

  NCT03994471· Phase 3· Source

• Recruiting

  Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

  NCT05924100· Phase 2· Source

• Not yet recruiting

  Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)

  2024-520326-11-00· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Source

• Recruiting

  A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

  NCT05001087· Source

• Active, not recruiting

  An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

  NCT04717414· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma2 recruiting
• Acute myeloid leukemia1 recruiting
• Chronic kidney disease1 recruiting
• Myelodysplastic syndromes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.

  NCT06230224· Phase 3· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Source